RSLV-132 (RNase1-Fc fusion) in post-acute COVID-19 (long COVID)
Post-acute COVID-19
Enrolment: 112 · Results not recorded
Loading the evidence…
Biologic
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Post-acute COVID-19
Enrolment: 112 · Results not recorded
Systemic Lupus Erythematosus
Enrolment: 64 · Results not recorded
Primary Sjogren Syndrome
Enrolment: 106 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Superior mesenteric artery clamped for 1 h followed by 2 h reperfusion
RNase treatment reduced inflammatory cytokine production, inhibited intestinal apoptosis and downregulated Toll-like receptor 3 expression after intestinal ischaemia-reperfusion, consistent with a causal role for raised extracellular RNA.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.